Ken Kengatharan, Phd Mba Email & Phone Number

Santa Clara, CA, US

Roscrea, Co. Tipperary, IE

Renexxion, Inc. is a US-based biotechnology company with a wholly owned Irish subsidiary; Renexxion Ireland Limited. ​We are committed to delivering innovative drugs to patients with a high unmet need in gastrointestinal disorders with its pipeline in a pill: Naronapride. [see www.renexxion.com]

Roscrea, Co. Tipperary, IE

Renexxion Ireland Ltd. is a privately held biopharmaceutical company committed to delivering new drugs to patients with GI motility disorders with its R&D operations and drug development team based in Ireland. The company is developing naronapride, a potentially best-in-class, late-phase clinical-stage drug candidate that possesses a unique combination of.

Roscrea, Co. Tipperary, IE

Roscrea, Co. Tipperary, IE

Santa Clara, California, US

Atheneos Ventures is a San Francisco Bay Area based healthcare focused evergreen fund dedicated to identifying and nurturing high quality, high risk (and potentially) game-changing healthcare companies previously focused on large indications and currently focusing on the orphan drugs and rare diseases space. [www.atheneosventures.com]

Apollorion global is a corporate strategy advisory firm that partners with innovative healthcare companies to foster their growth. We deploy an experienced team that will work with the founders and senior leadership to execute on their vision. Where necessary, working with affiliates, we provide a comprehensive one-stop solution. Activities include.

Radix Blend is a tech-enabled functional nutrition company developing an innovative way to create and deliver precision and personalized nutrition tied to feedback on health performance such as systemic glucose bioavailability. [Stage: Deep Stealth Mode]

Santa Clara, California, US

Helios Orion, Corp. is an execution-focused corporate strategy advisory firm that partners with innovative healthcare and cleantech companies in key global markets to assist in their growth. The company's network has deep domain-specific expertise in all areas of corporate development and product development from discovery/prototype to commercialization in.

Santa Clara, California, US

The goal of Auxesia Orion, Inc. is to focus on tech-enabled patient-centric therapeutics management and commercialization for orphan diseases where drugs are only part of a solution. The company is involved in research and development, approval and technology-enabled commercialization of novel drugs for orphan diseases as well as patient centric-management.

Santa Clara, California, US

The goal of Auxesia Orion, Inc. is to focus on tech-enabled patient-centric therapeutics management and commercialization for orphan diseases where drugs are only part of a solution.

Strategic Business AdvisorExecutive CoachCorporate Development Advisor

SPIRE Bioventures is a group of senior executives whose aim is to guide European Medical devices and biotech Start-ups gain visibility in the Bay Area ecosystem. The SPIRE Bioventures partners are dedicated equity partners who work together closely in a closed Network, serving customers as international consultants, advisors and board members. Website.

Santa Clara, California, US

Armetheon is a cardiovascular focused late-clinical stage specialty pharmaceutical company. In Q3, 2017, Armetheon merged with Espero Pharmaceuticals, Inc to become Espero BioPharma, Inc, a commercial-stage cardiovascular focused company with 3 marketed products and a potential blockbuster pipeline. [www.esperobio.com]

Santa Clara, California, US

Armetheon is a cardiovascular focused late-clinical stage specialty pharmaceutical company developing a potentially best-in-class, novel, orally active anticoagulant (tecarfarin) for all patients who need an oral anticoagulant including a targeted patient population with major unmet need. Unlike non-monitored oral anti-coagulant (NOAC) drugs that are.

Santa Clara, California, US

Armetheon is a cardiovascular focused late-clinical stage specialty pharmaceutical company developing a potentially best-in-class, novel, orally active mid- late- stage drug candidates for defined high unmet need patient population. See above/website for additional info [www.armetheon.com]

Santa Clara, California, US

Armetheon is a cardiovascular focused late-clinical stage specialty pharmaceutical company developing a potentially best-in-class, novel, orally active mid- late- stage drug candidates for defined high unmet need patient population. See above/website for additional info [www.armetheon.com]

Altheos is a biopharmaceutical company focused on the development of a new generation of promising, novel, small-molecule drugs for the treatment of ocular diseases in particular glaucoma. As President & CSO, I was responsible for all non-clinical and CMC activities related to the development of a new generation of topical eye drop therapy for glaucoma.

Altheos is a biopharmaceutical company focused on development of a new generation of promising, novel, small-molecule drugs for the treatment of ocular diseases in particular glaucoma. See above.

South San Francisco, CA, US

CoMentis, Inc. is focused on the research and development of small molecule drugs to treat Alzheimer's disease and is at present mainly pursuing the development of beta-secretase inhibitor drugs in partnership with Astellas Pharma, Inc., under terms of an exclusive worldwide collaboration agreement initiated in 2008. As head of Pre-Clinical R&D (South San.

South San Francisco, CA, US

Athenagen was founded based on technologies discovered at Stanford University to discover and develop drugs in the area of cholinergic angiogenesis. The company later acquired Osprey pharmaceutical which was developing novel alpha-7 nicotinic receptor agonists for cognitive dysfunction in various neurological disorders. As head of non-clinical R&D.

South San Francisco, CA, US

Athenagen was founded based on technologies discovered at Stanford University to discover and develop drugs in the area of cholinergic angiogenesis. The company later acquired Osprey pharmaceutical which was developing novel alpha-7 nicotinic receptor agonists for cognitive dysfunction in various neurological disorders. As head of non-clinical R&D.

Palo Alto, CA, US

Characterization of a novel angiogenesis pathway discovered at Stanford and identifying new therapeutic uses for agents that modulated this pathway. This angiogenic pathway is termed "Cholinergic Angiogenesis." This scientific work was the basis of founding Athenagen, Inc. in 2004 that was later re-named CoMentis, Inc in 2007 when the company became a.

OxoN Medica was developing novel nitric oxide donors that were also superoxide dismutase (SOD) mimetics. As head of non-clinical R&D, I was responsible for development of NCEs for angina, vascular complications in diabetes and neuroprotection in glaucoma.

Founded by scientists, clinicians and IT experts, ePi3 was one of the early pioneers tasked with creating a comprehensive digital system for efficiently carrying out scientific research and drug development. ePi3 engaged Unisys Corporation (UK), an American global IT company, which made multi-million dollar commitment, and provided a team of 35 people.

As a member of the discovery team within Cardiovascular group, I was given the responsibility to set up a secondary screening laboratory to help identify novel endothelin receptor antagonists. Endothelin, a potent vasoconstrictor peptide, was discovered a couple of years earlier.

Post-Doctoral Fellowship, Cardiovascular Pharmacology

Mba (With Distinction), Specializing In Biotech Finance And Entrepreneurship

Phd, Pharmacology

Bsc, Pharmacology